3 days popular7 days popular1 month popular3 months popular

Anti-Melanoma Vaccine Tested For Anti-Cancer Immune Response

Cancer vaccines prime the to attack cancer cells, decreasing . IL-12p70, a molecule produced by certain types of immune cells, has been shown to reduce , but delivering it as part of a has been limited because of its toxicity in high doses.

In the current issue of the , Dr. and colleagues at Washington University report the results of a clinical trial that tested a vaccine to treat newly diagnosed advanced melanoma. A portion of each patient’s own immune cells, known as dendritic cells, were modified to stimulate increased production of IL-12p70 by their immune system. This method avoided the toxicity seen with previous approaches. Carreno and colleagues found that IL-12p70 enhanced the effectiveness of the vaccine. Six out of seven patients exhibited a vaccine-stimulated and three patients exhibited clinically significant changes in the progression of their tumors. These results underscore the role of IL-12p70 in the development of an anti-cancer .

This study was funded Barnes-Jewish Hospital Foundation, Siteman Cancer Frontier Fund, Washington University/JNJ Translational Medicine Awards, and the National Cancer Institute. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

TITLE: IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity

http://www.jci.org/articles/view/68395?key=1d2f8ff3a42086043c24

Source

Journal of Clinical Investigation